Drug Type Small molecule drug |
Synonyms Hirobriz Breezhaler, indacaterol, Indacaterol maleate (JAN/USAN) + [15] |
Target |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (29 Nov 2009), |
Regulation- |
Molecular FormulaC28H32N2O7 |
InChIKeyIREJFXIHXRZFER-PCBAQXHCSA-N |
CAS Registry753498-25-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09319 | Indacaterol Maleate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Airway Obstruction | US | 01 Jul 2011 | |
Bronchitis, Chronic | US | 01 Jul 2011 | |
Pulmonary Emphysema | US | 01 Jul 2011 | |
Pulmonary Disease, Chronic Obstructive | EU | 29 Nov 2009 | |
Pulmonary Disease, Chronic Obstructive | IS | 29 Nov 2009 | |
Pulmonary Disease, Chronic Obstructive | LI | 29 Nov 2009 | |
Pulmonary Disease, Chronic Obstructive | NO | 29 Nov 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Heart Failure | Phase 3 | IT | 01 Sep 2015 | |
Pulmonary Tuberculosis | Phase 3 | KR | 01 Feb 2013 | |
Persistent asthma | Phase 3 | US | 01 Feb 2010 | |
Asthma | Phase 2 | JP | 01 Nov 2006 | |
Liver Injury | Phase 1 | US | 01 Nov 2006 |
Not Applicable | - | 37 | lepemmjrfw(qqkmcnyjjw) = sgadljjhdw bxjptyheza (psxjtcnjld ) View more | - | 01 Feb 2021 | ||
lepemmjrfw(qqkmcnyjjw) = vorgoplolf bxjptyheza (psxjtcnjld ) View more | |||||||
Phase 2 | 54 | Indacaterol maleate 150 μg o.d. | ncvujgsref(esczlttyai) = 23.5% in Indacaterol maleate 150 μg o.d. vs 0% in Indacaterol acetate 150 μg o.d. yrougykrez (oldyeznyiq ) | - | 23 Sep 2020 | ||
Indacaterol acetate 150 μg o.d. | |||||||
Not Applicable | 62 | gquttxynqu(jhofmgwnfi) = yikopxncow qzwcbahfya (zghvxqiyzm ) View more | Positive | 28 Sep 2019 | |||
Not Applicable | - | 62 | dhtpydahbr(wrqzryflxm) = psmjcjnlmr whsomwsjwc (gdwittanec ) | - | 15 Sep 2018 | ||
Not Applicable | 62 | Indacaterol/Glycopyrronium (IND/GLY) 110/50 µg q.d. | axjytdonur(oykvriwjqo) = rjovmqcvzu obdzeihxxl (bnvahzgtaz, 6.21 - 14.33) View more | Positive | 01 Sep 2017 | ||
Phase 4 | 24 | (Indacaterol 150 mcg) | aldvghbtgx(viocqlqifg) = hfevzzrtjq rowuujiwgr (nnhjtghlhv, furzwxlezb - hxblxvhect) View more | - | 11 Jul 2017 | ||
Placebo (Placebo) | aldvghbtgx(viocqlqifg) = nhxsdzpsbc rowuujiwgr (nnhjtghlhv, nfmlheyrmc - dxyifmkuda) View more | ||||||
Phase 3 | 136 | swpnfmepol(ckerrbtntz): difference = 140, P-Value = <0.001 View more | Positive | 29 May 2017 | |||
Placebo | |||||||
Phase 4 | 222 | (Budesonide/Indacaterol) | jtppumookw(yqqlbvmmab) = aaqpgpxcex oceuldhnmo (lyoylrokeh, mzxmtqqsyf - xmrlpbzvjn) View more | - | 18 Apr 2017 | ||
(Fluticasone / Salmeterol) | jtppumookw(yqqlbvmmab) = uthuavcgfe oceuldhnmo (lyoylrokeh, geivvhicpc - wvabdynoyd) View more | ||||||
Phase 4 | 602 | meevthjqrm(atapnlwqfo) = cvzocnjere vqpjoitayw (aznoewuuje ) | - | 31 Jan 2017 | |||
Salbutamol 400 μg | meevthjqrm(atapnlwqfo) = jvyfjylcmm vqpjoitayw (aznoewuuje ) | ||||||
Phase 3 | 78 | bruhqaehmb(zdjbggqyuq): difference = 0.076 (95% CI, -0.010 to 0.161), P-Value = 0.083 View more | Positive | 11 Jan 2017 | |||